Alector Management

Management criteria checks 2/4

Alector's CEO is Arnon Rosenthal, appointed in Jan 2013, has a tenure of 11.25 years. total yearly compensation is $4.26M, comprised of 15.4% salary and 84.6% bonuses, including company stock and options. directly owns 5.58% of the company’s shares, worth €26.41M. The average tenure of the management team and the board of directors is 2.3 years and 5.1 years respectively.

Key information

Arnon Rosenthal

Chief executive officer

US$4.3m

Total compensation

CEO salary percentage	15.4%
CEO tenure	11.3yrs
CEO ownership	5.6%
Management average tenure	2.3yrs
Board average tenure	5.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Arnon Rosenthal's remuneration changed compared to Alector's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$4m	US$654k	-US$130m
Sep 30 2023	n/a	n/a	-US$141m
Jun 30 2023	n/a	n/a	-US$143m
Mar 31 2023	n/a	n/a	-US$135m
Dec 31 2022	US$4m	US$621k	-US$133m
Sep 30 2022	n/a	n/a	-US$136m
Jun 30 2022	n/a	n/a	US$36m
Mar 31 2022	n/a	n/a	-US$29m
Dec 31 2021	US$10m	US$575k	-US$36m
Sep 30 2021	n/a	n/a	-US$33m
Jun 30 2021	n/a	n/a	-US$212m
Mar 31 2021	n/a	n/a	-US$202m
Dec 31 2020	US$4m	US$554k	-US$190m
Sep 30 2020	n/a	n/a	-US$169m
Jun 30 2020	n/a	n/a	-US$148m
Mar 31 2020	n/a	n/a	-US$127m
Dec 31 2019	US$7m	US$525k	-US$105m
Sep 30 2019	n/a	n/a	-US$92m
Jun 30 2019	n/a	n/a	-US$76m
Mar 31 2019	n/a	n/a	-US$62m
Dec 31 2018	US$5m	US$397k	-US$52m
Sep 30 2018	n/a	n/a	-US$45m
Jun 30 2018	n/a	n/a	-US$39m
Mar 31 2018	n/a	n/a	-US$35m
Dec 31 2017	US$3m	US$370k	-US$32m

Compensation vs Market: Arnon's total compensation ($USD4.26M) is above average for companies of similar size in the German market ($USD1.02M).

Compensation vs Earnings: Arnon's compensation has increased whilst the company is unprofitable.

CEO

Arnon Rosenthal (67 yo)

11.3yrs

Tenure

US$4,255,007

Compensation

Dr. Arnon Rosenthal, Ph D., Co-Founded of in 2013 and serves as its Chief Executive Officer and Director since 2013 and served as its President since 2013. He served as Chief Scientific Officer of Alector,...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Arnon Rosenthal	Co-Founder	11.3yrs	US$4.26m	5.58% $ 26.4m
Saraswati Kenkare-Mitra	President and Head of Research & Development	2.3yrs	US$2.61m	0.059% $ 281.5k
Marc Grasso	CFO, Principal Financial Officer & Principal Accounting Officer	2.2yrs	US$1.72m	0.023% $ 106.9k
Gary Romano	Chief Medical Officer	1.9yrs	US$1.62m	0.059% $ 277.6k
Peter Heutink	Chief Scientific Officer	2.3yrs	no data	no data
Katie Hogan	Senior Director of Corporate Communication & Investor Relations	no data	no data	no data
Danielle Pasqualone	General Counsel	2.3yrs	no data	no data
Clare Hunt	Chief People Officer	no data	no data	no data
Kristina Cutter	Chief Regulatory	no data	no data	no data
Virginia DeJesus-Rueff	Chief of Staff & Head of Strategy	2.3yrs	no data	no data
Norah Conway	Senior Vice President of Portfolio & Program Management	2.3yrs	no data	no data
Neil Berkley	Chief Business Officer	less than a year	no data	no data

2.3yrs

Average Tenure

55yo

Average Age

Experienced Management: 0Z2's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Arnon Rosenthal	Co-Founder	11.3yrs	US$4.26m	5.58% $ 26.4m
Louis Lavigne	Independent Chairperson of the Board	5.5yrs	US$355.07k	0.0099% $ 46.7k
Richard Scheller	Director & Member of Scientific Advisory Board	5.5yrs	US$509.13k	0.0099% $ 46.7k
Thomas Sudhof	Member of Scientific Advisory Board	no data	no data	no data
Stephen Hauser	Member of Scientific Advisory Board	no data	no data	no data
David Wehner	Independent Director	5.5yrs	US$324.71k	0.056% $ 267.2k
Adam Boxer	Member of Scientific Advisory Board	no data	no data	no data
Paula Hammond	Independent Director	4.1yrs	US$318.92k	0.0099% $ 46.7k
Kristine Yaffe	Independent Director	4.7yrs	US$318.12k	0.0099% $ 46.7k
Michael Heneka	Member of Scientific Advisory Board	no data	no data	no data
Martin Kampmann	Member of Scientific Advisory Board	2.3yrs	no data	no data
Elizabeth Garofalo	Independent Director	2.6yrs	US$322.27k	0% $ 0

5.1yrs

Average Tenure

66yo

Average Age

Experienced Board: 0Z2's board of directors are considered experienced (5.1 years average tenure).

Alector Management

Management criteria checks 2/4

Key information

Recent management updates

Alector, Inc., Annual General Meeting, Jun 12, 2024

Co-Founder recently sold €120k worth of stock

Insufficient new directors

Insufficient new directors

Co-Founder recently sold €122k worth of stock

Co-Founder recently sold €89k worth of stock

Recent updates

Alector, Inc., Annual General Meeting, Jun 12, 2024

Co-Founder recently sold €120k worth of stock

Alector, Inc. Provides Revenue Guidance for the Year Ending 2024

Full year 2023 earnings released: US$1.56 loss per share (vs US$1.62 loss in FY 2022)

Alector, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Alector Announces First Patient Dosed in Progress-Ad Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’S Disease

Alector, Inc. has completed a Follow-on Equity Offering in the amount of $71.413049 million.

New minor risk - Shareholder dilution

Alector, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Insufficient new directors

Insufficient new directors

New major risk - Revenue and earnings growth

Co-Founder recently sold €122k worth of stock

Alector, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Alector, Inc. Reiterates Earnings Guidance for the Year Ending 2023

Third quarter 2023 earnings released: US$0.53 loss per share (vs US$0.56 loss in 3Q 2022)

Alector, Inc. Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to Progranulin Gene Mutation (FTD-GRN)

Alector, Inc. Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002

Second quarter 2023 earnings released: EPS: US$0.016 (vs US$0.12 in 2Q 2022)

Alector, Inc. to Report Q2, 2023 Results on Aug 03, 2023

First quarter 2023 earnings released: US$0.55 loss per share (vs US$0.54 loss in 1Q 2022)

Alector, Inc. Provides Revenue Guidance for the Year 2023

Co-Founder recently sold €89k worth of stock

Key Executive recently sold €79k worth of stock

Full year 2022 earnings released: US$1.62 loss per share (vs US$0.45 loss in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.56 loss per share (vs US$1.56 profit in 3Q 2021)

Alector, Inc. Announces Promotion of Clare Hunt to Chief People Officer

Alector, Inc. Announces Resignation of Robert King as Chief Development Officer

Alector, Inc. Initiates Phase 1 Clinical Trial of Al044 for the Treatment of Alzheimer’s Disease

Second quarter 2022 earnings released: EPS: US$0.12 (vs US$0.69 loss in 2Q 2021)

Alector, Inc Developing AL003 to Treat Patients with Alzheimer's Disease as One of Two Programs Pursuant to the Co-Development and Option Agreement

First quarter 2022 earnings released: US$0.54 loss per share (vs US$0.66 loss in 1Q 2021)

Insufficient new directors

Alector, Inc. Announces Appointment of Gary Romano as Chief Medical Officer

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Forecast breakeven date pushed back to 2023

Alector, Inc. Announces Executive Changes

Forecast breakeven date pushed back to 2022

Third quarter 2021 earnings released: EPS US$1.56 (vs US$0.67 loss in 3Q 2020)

Insufficient new directors

Alector Announces First Participant Dosed in Phase 2 Study Evaluating Al001 in Amyotrophic Lateral Sclerosis (Als)

Forecast to breakeven in 2021

Forecast to breakeven in 2023

Second quarter 2021 earnings released: US$0.69 loss per share (vs US$0.58 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.66 loss per share (vs US$0.54 loss in 1Q 2020)

Advisor has left the company

Revenue misses expectations

Full year 2020 earnings released: US$2.45 loss per share (vs US$1.71 loss in FY 2019)

New 90-day high: €16.40

Alector, Inc. Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer’s Disease

Alector, Inc. Announces Executive Changes

New 90-day high: €13.70

New 90-day high: €12.40

Revenue misses expectations

Third quarter 2020 earnings released: US$0.67 loss per share

New 90-day low: €8.50

New 90-day low: €9.45

New 90-day low - €10.70

First half earnings released

New 90-day low - €14.50

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members